Coronavirus Highlights: India Logs 14,917 Covid Cases, 32 Related Deaths

Hyderabad district saw the highest number of cases with 142.

A health department bulletin said 528 people recuperated from the infection and the cumulative number of recoveries till date was 8,22,173.

The recovery rate stood at 99.12 per cent.

No fresh fatality occurred due to the infectious disease and the death count continued to be 4,111.

The number of active cases was 3,183.

The recovery count stood at 11,55,276 after 351 people were discharged during the day, leaving the state with 1,542 active cases, he said.

"Raigarh led with eight cases, followed by seven in Korba, six in Raipur, five in Rajnandgaon, three in Bilaspur and two in Durg, among other districts. No coronavirus case was reported in 13 districts," he said.

The death count remained unchanged at 21,422 as no fresh fatality was recorded.

The state had reported 479 cases and two deaths on Sunday.

There are now has 5,299 active cases, of whom 151 are hospitalised, while 658 more people were cured of the disease, taking the total number of recoveries to 20,76,036.

A total of 13,653 people received vaccine jabs on Monday.

The positivity rate, or cases detected per 100 tests, stood at 1.9 per cent, he added.

The recovery count increased by 162 and touched 10,40,700, leaving the state with 847 active cases, the official informed.

A government release said 12,66,73,721 COVID-19 vaccine doses have been administered so far in the state, including 576 on Monday.

The active cases on Sunday stood at 7,406.

As many as 964 people were cured of the virus, pushing the overall recoveries to 35,14,313.

Total cases so far were 35,59,491.

There were no virus-related deaths, the bulletin said.

The addition to the tally was a significant drop from the 599 cases registered a day ago, he pointed out.

The recovery count rose by 635 and touched 12,51,031, leaving the state with 3,719 active cases, he said.

The two deaths took place in Ahmedabad, which also accounted for 105 of the new cases, followed by 42 in Vadodara, 29 in Surat, among other districts, he said.

A government release said 58,975 people got COVID-19 vaccine jabs on Monday, which took the overall number of doses administered in the state to 12 crore.

Of the new cases, 34 were reported from Jammu division and 239 from the Kashmir valley, they said.

There are 4,154 active cases while the overall recoveries has reached 4,65,122, officials said.

The COVID-19 death count rose to 776 as one more person succumbed to the disease in Kohima, he said.

The state currently has 36 active COVID-19 cases, while 33,551 people have recovered from the disease and 1,508 patients have migrated to other states, the official said.

A total of 17,11,174 coronavirus vaccines have been administered in the state till Saturday, the official added.

This is a drop from the 882 cases and one death recorded on Sunday, the Brihanmumbai Municipal Corporation official pointed out.

Of the new cases, 522 are asymptomatic, he added.

The recovery count increased by 407 in the last 24 hours to touch 11,08,290, which left the metropolis with an active caseload of 5,218, the official said.

BMC data showed the recovery rate was 97.8 per cent and the growth rate of cases between August 8 and 14 stood at 0.062 per cent.

A day earlier, the state had seen 2,082 cases and three deaths.

Mumbai accounted for 584 of the new cases, while the lone death took place in Panvel Municipal Corporation limits in the Raigad district, the official said.

So far, 79,13,209 persons have recovered, including 1,142 in the last 24 hours, leaving the state with 12,148 active cases, he said.

State health department data showed the recovery rate was 98.01 per cent and the fatality rate was 1.83 per cent.

All positive cases were reported in Leh.

So far, 228 people have succumbed to Covid in Ladakh. Of these, 168 deaths were reported from Leh and 60 from Kargil, according to the officials.

While the number of active COVID-19 cases has come down to 73 in Ladakh.

The vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries, a press release from the vaccine maker said.

BBV154 was developed in partnership with Washington University St Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy.

The Centre partially funded product development and clinical trials through the Department of Biotechnology's, COVID Suraksha programme.

Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (2-dose) schedule and a heterologous booster dose for subjects who have previously received 2 doses of the two commonly administered Covid vaccines in India.

The Union territory now has 18 active cases, while 10,367 people have recovered from the disease so far, including six in the last 24 hours.

A total of 129 patients have succumbed to the infection to date.